🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Swiss stocks - Factors to watch on Nov. 19

Published 19/11/2018, 06:08 pm
© Reuters.  Swiss stocks - Factors to watch on Nov. 19
SWI20
-
ABBN
-
NOVN
-
NESN
-
AIR
-
GOOGL
-
RIO
-
GSK
-
ULVR
-
RIO
-
OERL
-
6501
-
COPN
-
DKSH
-
GOOG
-
MOZN
-
DOCM
-

ZURICH/BERLIN, Nov 19 (Reuters) - The Swiss blue-chip SMI .SSMI was seen opening 0.2 percent higher at 8,926 points, according to premarket indications from bank Julius Baer JBPRE01 .

Here are some of the main factors that may affect Swiss stocks on Monday:

ABB ABBN.S

Talks between ABB and Hitachi 6501.T on a sale of all or parts of ABB's power grid business are at a "fairly developed stage", but a deal is not yet assumed and the potential value of the transaction still unknown, the Financial Times reported, citing people close to the matter. NESN.S

Nespresso aims to use sustainable aluminium in all of its coffee capsules by 2020 under a deal with mining major Rio Tinto RIO.L RIO.AX . Nestle's Indian business is pitted against Unilever (LON:ULVR) in the final round of negotiations for GlaxoSmithKline's GSK.L consumer nutrition business in India, the Economic Times reported.

For more, click on NESN.S

NOVARTIS NOVN.S

* Novartis said the U.S. Food and Drug Administration expanded the use of its low platelets drug to treat patients with a rare, genetic blood disorder. Additionally, Alphabet's GOOGL.O life sciences division Verily said that it was putting on hold a smart contact lens designed to help monitor sugar levels. Verily had partnered with Novartis' Alcon to develop the lens. more, click on NOVN.S

RAIFFEISEN SWITZERLAND RFSHW.UL

Raiffeisen Switzerland is seeking to have its purchase of private equity firm Investnet annulled, SonntagsZeitung reported, months after financial market supervisor FINMA found the bank's handling of conflicts of interest was inadequate, including in relation to that transaction. are investigating former Chief Executive Pierin Vincenz, who denies wrongdoing, on suspicion of breach of trust linked to cashless payments business Aduno as well as Investnet.

COMPANY STATEMENTS E-CH

* Cosmo Pharmaceuticals COPN.S said the U.S. Food and Drug Administration had approved a new drug to treat travellers' diarrhoea. COPN.S

* DKSH DKSH.S said Martina Ludescher, Chief Commercial Officer, Head Business Unit Consumer Goods and Member of the Executive Board, will leave the company to pursue other challenges. DKSH.S

* Mobilezone MOZN.S Chief Executive Markus Bernhard said in an interview with Cash the company was confident to reach its 2018 targets, would likely generate a net profit of at least 35 million Swiss francs and did not see a reason to cut its dividend. He also said the company was interested in doing acquisitions or might itself become a target. MOZN.S

* Oerlikon OERL.S said it deepened its partnership with Airbus AIR.PA , having received a qualified supplier status. OERL.S

* Zur Rose ROSEG.S announced the terms of its 200 million Swiss franc ($199.90 million) capital increase to finance the medpex acquisition as well as further organic growth initiatives. ROSEG.S

ECONOMY M-CH

* The Swiss National Bank's policy of negative rates combined with the ability to intervene in currency markets if needed is appropriate given risks such as Brexit, SNB Governing Board member Andrea Maechler said. Standard & Poor's affirmed Switzerland's rating at 'AAA/A-1+', outlook stable. ($1 = 1.0005 Swiss francs)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.